• Caught in the debt trap?

    Help us help you by taking our second annual Debt survey and you could win R3 000.

  • Rich man, poor man

    Culture change from below is the only way to overcome poverty, says Leopold Scholtz.

  • Tech bubble talk

    After the tech euphoria of 2013, the fast-moving sector has hit a speed bump.

Data provided by McGregor BFA
All data is delayed
Loading...
See More

Govt awards R6bn HIV drugs contract

Nov 29 2012 15:12 Reuters
HIV-ARV

(File) (Shutterstock)

Company Data

ASPEN PHARMACARE HOLDINGS LIMITED [JSE:APN]

Last traded 273.96
Change 3.96
% Change 0.01
Cumulative volume 1145346
Market cap 125.02bn

Last Updated: 24/04/2014 at 04:29. Prices are delayed by 15 minutes. Source: McGregor BFA

ADCOCK INGRAM HOLDINGS LIMITED [JSE:AIP]

Last traded 60.11
Change 0.21
% Change 0.00
Cumulative volume 244004
Market cap 10.56bn

Last Updated: 24/04/2014 at 04:28. Prices are delayed by 15 minutes. Source: McGregor BFA

Related Articles

Aspen boosts profit, Asian unit robust

Aspen: Earning to between rise 18%-24%

Aspen buys GSK Aussie drugs for R2.2bn

Drug firms win R2.5bn tender

Aspen unit to buy drug portfolio from GSK

Aspen prepared to help bridge ARV shortages

 

Johannesburg - South Africa on Thursday awarded a R5.9bn contract to supply life-prolonging HIV medicine to 12 international and domestic firms, to deal with the country's biggest health problem.

Companies that include Aspen Pharmacare Holdings [JSE:APN], Abbott Laboratories and Adcock Ingram Holdings [JSE:AIP] would share the contract, the health department said.

The R5.9bn contract, effective from April next year, aims to increase the number of people on treatment by nearly 50%, to 2.5 million next year.

South Africa has nearly 6 million people infected with HIV - one of the heaviest caseloads in the world. It also has one of largest treatment programmes.

But drug makers are unlikely to rake in big profits from the government award, analysts have said, given the stiff competition in the bidding.

The health department said it saved R2.2bn on the new contract, which it initially expected it would cost R8.1bn.

Aspen Pharmacare, the country's biggest generic drugs maker, was awarded 20% of the contract while its closest domestic rival, Adcock Ingram was given 14%, the health department said.

Other contracts winners included Chicago-based Abbott Laboratories with 8.1%, and domestic firm Cipla Medpro South Africa [JSE:CMP] with 9%.

 

Follow Fin24 on Twitter and Facebook

NEXT ON FIN24X

AstraZeneca seeking deals

2014-04-24 14:50

 
 
 

Read Fin24’s Comments Policy

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
19 comments
Add your comment
Comment 0 characters remaining
 

Company Snapshot

We're Talking About: Small Business

Standard Bank is looking for 12 entrepreneurs to participate in a 10-part TV series. They could win a R1m investment into their dream.
 
 

The rich will pay - Mpofu

The EFF in Gauteng will focus all its energy on improving the lives of the poor, the party's premier candidate Dali Mpofu says.

 
 

Latest elections multimedia

Watch what happened when we blindfolded Helen Zille and asked her to eat random things
13 days to elections - news you need to know
11 Julius Malema quotes you'll never forget
DA won't get 30% - Zille

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...
Loading...